Compare AbbVie Inc (ABBV) vs EPR Properties (EPR) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

EPR Properties trades at $62.20, up 1.4% today, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company shows strong profitability with a 91.41% gross margin and raised 2026 FFO guidance, supported by a new $1.6 billion credit facility announced on July 20, 2026. Key resistance is at $63, with support at $61.

Outlook is cautiously positive given analyst consensus of $65.30 price target and dividend stability, but risks include declining net income margins and high valuation multiples. Investment appeal hinges on execution of acquisition strategy amid economic sensitivity.